top of page

Atorvia accepted into the Creative Destruction Labs program

We are thrilled to announce that Atorvia will participate as one of the Ventures at the CDL-Berlin accelerator program in the 2023/24 Health Stream cohort as we take another important step on our journey to #BuildSomethingMassive and revolutionize treatment for organ failure, beginning with a kidney franchise initially targeting Acute Kidney Injury.  

Read more about the program here:

We are pleased to announce Atorvia will be one of the 20 companies pitching at MassBio Align Summit w/ insights by McKinsey & Company. The day will include keynotes, panel discussions, and pitches from other innovative seed/series A #biotech#healthtech, and #medtech start-ups. Plus, attendees will have the opportunity to set up their own 1:1 partnering meetings with investors throughout the day. #AlignSummit

Register to hear our pitch here:

Atorvia to present at MassBio Align Summit 

Atorvia to present at McKinsey ESIC 2022 

Come meet us at McKinsey's #ESIC2022 Conference on June 23rd and learn more about the work we are doing to develop new and life-saving technologies for patients with organ failure, with our first program in Acute Kidney Injury.

MassBio Accelerator S22

Atorvia successfully graduated from the prestigious #Massbio accelerator program, #MassBioDrive spring 2022 cohort, one of only 7% of companies applying to be accepted into the program.

Learn more about MassBioDrive and the spring 2022 cohort here:

bottom of page